echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Novartis' generic drug unit Sandoz may sell for US$21.6 billion

    Novartis' generic drug unit Sandoz may sell for US$21.6 billion

    • Last Update: 2021-12-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compiler: Fan Dongdong

    A few days ago, news showed that Novartis may divest its generic drug division Sandoz (Sandoz) in the process of promoting the divestiture of its generic drugs and consumer businesses across the industry


    If it succeeds in the end, the acquisition amount of more than 20 billion U.


    According to reports, Thomas and Andreas of the Struengmann family sold the generic drug company Hexal to Novartis in 2005, and the company has also become part of Sandoz


    It is not uncommon for large pharmaceutical companies to adjust their generic drug business


    Without the approval of the US FTC, Sandoz terminates the transaction of US$1 billion worth of pharmaceutical assets

    In 2018, when Novartis revealed a plan to grant Sandoz more autonomy, similar to the divestiture of other pharmaceutical giants, this move was designed to allow them to focus on high-risk, high-return drug development businesses


    Like many other generic drug manufacturers, Sandoz has been struggling to cope with falling prices in the US market


    Reference source:

    1.


    2.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.